- JPMorgan initiates athenahealth (ATHN +0.1%), Allscripts (MDRX), and MedAssets (MDAS -1.7%) at Overweight, Overweight, and Neutral, respectively.
- On ATHN: The company "offers highly rated products differentiated from competitors' because of SaaS-based functionality and supportive back-office operations." Price target is $155.
- On MDRX: "We believe the growing share of recurring revenues, in part due to the company's large installed physician base, combined with recent bookings trends, sets the company up well for improving trends in 2014." Price target is $18.
- On MDAS: "While we like the company's positioning in both the revenue cycle and group purchasing markets, we are concerned about the impact from utilization trends on the SCM business and the volatility experienced in the RCM business." Price target is $23.